A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity

Blood

Volumn 94, Issue 10, 1999, Pages 3307-3314

  Gordon, Leo I ^a   Young, Mary ^b   Weller, Edie ^b   Habermann, Thomas M ^b   Winter, Jane N ^b   Glick, John ^b   Ghosh, Chirantan ^b   Flynn, Patrick ^b   Cassileth, Peter A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; DRUG EFFECT; FEMALE; FEVER; GENETIC ANALYSIS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; VOMITING;

EID: 0033570984     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.10.3307.422k11_3307_3314     Document Type: Article

References (39)

1. Armitage J: Drug therapy: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023, 1993
2. Anderson JR, Vose JM, Bierman PJ, Weisenberger DD, Sanger WG, Pierson J, Bart M, Armitage JO: Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol 11:218, 1993
3. Aviles A, Yanez J, Lopez T, Garcia EL, Guzman R, Diaz-Maqueo JL: Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma. Arch Med Res 26:31, 1995
4. Aviles A, Zepeda G, Diaz-Maqueo JC, Rodriguez L, Guzman R, Garcia EL, Tulavera A: Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma. Leuk Lymphoma 7:135, 1992
5. Coiffier B: Prognostic factors in large-cell lymphomas. Pathol Biol (Paris) 41:92, 1993
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
7. Gascoyne RD: Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 11:847, 1997
8. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244, 1997
9. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC: Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:3173, 1997
10. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342, 1992
11. Kovner F, Merimsky O, Inbar M, Soyfer V, Cahan Y, Rachmani R, Chaitchik S: Prognostic importance of advanced age in aggressive non-Hodgkin's malignant lymphoma. Oncology 53:435, 1996
12. Hill ME, Maclennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC: Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 88:1046, 1996
13. Shipp M, Harris N, Mauch P: The Non-Hodgkin's Lymphomas. Philadelphia, PA, Lippincott, 1997
14. Nicolaides C, Fountzilas G, Zoumbos N, Skarlos D, Kosmidis P, Pectasides D, Karabelis A, Giannakakis T, Symeonidis A, Papadopoulos A, Antoniou F, Pavidis N: Diffuse large cell lymphomas: Identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 55:405, 1998
15. Winter J, Andersen J, Variakojis D, Gordon LI, Fisher RI, Oken MM, Neiman RS, Jiang S, Bauer KD: Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Blood 88:3919, 1996
16. Winter J, Andersen J, Reed J, Krajewski S, Variakojis D, Bauer KD, Fisher RI, Gordon LI, Oken MM, Jiang S, Jeffries D, Domer P: BCL-2 expression correlates with lower proliferative activity in the intermediate and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study. Blood 91:1391, 1998
17. Anderson JR, Santarelli MT, Peterson B: Dose intensity in the treatment of diffuse large-cell lymphoma. J Clin Oncol 8:1927, 1990 (letter; comment)
18. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, Robinson E, Cohen Y: Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66:1124, 1990
19. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y: Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24:533, 1988
20. Kwak LW, Halpern J, Olshen RA, Horning SJ: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963, 1990
21. Meyer RM, Hryniuk WM, Goodyear MD: The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 9:339, 1991
22. Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell VH, Weineman BH, Gospodarowicz MK, Burns BF, Sargeant AM, Shepherd LE: Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 329:1770, 1993
23. Gordon L, Andersen J, Habermann T, Winter JN, Glick J, Schilder RJ, Cassileth P: Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum tolerated dose of Pro-MACE-CytaBOM. J Clin Oncol 14:1275, 1996
24. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
25. Cox D: Analysis of Binary Data. London, UK, Methuen, 1970
26. Shipp MR: The international non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma. N Eng J Med 329:987, 1993
27. Gordon L, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, Cassileth PA: Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer 75:865, 1995
28. Yuen AR, Sikic BI: Multidrug resistance in lymphomas. J Clin Oncol 12:2453, 1994
29. Aviles A, Calva A, Diaz-Maqueo JC, Talavera A, Huestra-Guzman J, Vasquez E: Dose escalation of epirubicin in the CEOP-BLEO regimen: A controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma. Leuk Lymphoma 25:319, 1997
30. Cortelazzo S, Rossi A, Viero P, Bellavita P, Marchiolli R, Marfisi RM, Rambaldi A, Barbui T: BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol 99:379, 1997
31. Gianni A, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-b in aggressive B-cell lymphoma. N Engl J Med 336:1290, 1997
32. Gisselbrecht C, Bosly A, Lepage E, Reyes F, Philip T, Haioun C, Tilly H, Coiffier B: Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: A review. Ann Oncol 4:7, 1993
33. Longo DL: Chemotherapy for advanced aggressive lymphoma: More is better, isn't it? J Clin Oncol 8:952, 1990
34. Pettengell R, Crowther D: Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. Ann Oncol 5:133, 1994
35. Verdonck L, Von Putten WV, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JM, van Oers RH, Haak HL: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045, 1995
36. Shpilberg O, Shiff J, Chetrit A, Ramot B, Ben-Bassat I: The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients. Cancer 74:3029, 1994
37. Thirman M, Gill H, Burnett R, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-vander Poel S, Kaneko Y, Morgan R, Sandberg AA: Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 329:909, 1993
38. Travis L, Curtis R, Stovall M, Holowaty EJ, Van Leeuwen FE, Glimelius B, Lynch CF, Haganbeek A, Li CY, Banks PM: Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450, 1994
39. Deeg HJ, Socié G: Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood 91:1833, 1998